Skip to main content

Table 2 Best-Corrected Visual Acuity and Central Retinal Thickness Outcome at Month 12

From: Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study

Characteristic

IVC Group (n = 36)

IVR Group (n = 32)

Mean BCVA letter score at month 12 ± SD

58.7 ± 8.0

55.5 ± 9.6

Mean CRT at month 12 ± SD, μm

330.9 ± 77.2

328.7 ± 71.9

Mean change in BCVA letter score from baseline to month 12

 Mean ± SD

9.3 ± 5.2

8.9 ± 4.4

P value

0.756a

 

Mean CRT change from baseline to month 12 ± SD, μm

  

 Mean ± SD

−138.4 ± 97.7

−145.2 ± 72.5

P value

0.748a

 

Categorized BCVA letter score outcome at month 12, n (%)

 Gain of ≥5

30 (83.3)

26 (81.3)

 Gain of ≥10

15 (41.7)

13 (40.6)

 Gain of ≥15

7 (19.4)

5 (15.6)

  1. IVC intravitreal conbercept, IVR intravitreal ranibizumab, BCVA best-corrected visual acuity, CRT central retinal thickness, SD standard deviation
  2. aIndependent t test